Reducing Port Access Pain and Clinic Wait Time: An Evaluation of EMLA Cream Versus nüm™ Vapocoolant Spray

Marianne Hutti

Status and phase

Withdrawn

Phase 4

Conditions

Pediatric Cancer

Treatments

Drug: EMLA Cream

Drug: Num Vapocoolant Spray

Study type

Interventional

Funder types

Other

Identifiers

84569

Details and patient eligibility

About

The goal of this clinical trial is to compare a sterile vapocoolant spray to EMLA cream in children with access ports.

Participants will receive either the spray or cream prior to port access and rate pain on a scale.

Researchers will compare spray vs cream to see if the spray is as effective as the cream in reducing pain associated with port puncture.

Sex

All

Ages

4 to 18 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

English-speaking
Present appointment is for drawing blood, receiving intravenous antibiotics, blood products, or chemotherapy
EMLA cream has (standard of care) or has not (vapocoolant) been applied to the port site prior to the appointment
Previous allergic reaction or skin irritation due to EMLA
Quick access to the child's port is needed for drawing blood, or giving treatments, blood products, or drugs such as chemotherapy

Exclusion criteria

Child has a legal guardian or non-parent family member as the only adult with them for the visit.
Children less than 4 years of age
Children with altered mental status
History of traumatic brain injury, developmental delay or autism
Child is nonverbal
Present appointment is for drawing blood, receiving intravenous antibiotics, blood products, or chemotherapy, and child and parents prefer to wait for EMLA cream to take effect.